Silence Therapeutics Locks In $175M Upsized Offering with Underwriting Agreement
SLN has more than doubled off its 52-week low of $4.19 on elevated volume (6.6× avg).
Summary
Silence Therapeutics formalized its upsized $175 million underwritten public offering, selling 12.96 million ADSs at $13.50 each with net proceeds of approximately $164 million. The offering closed with underwriters fully exercising their option, bringing total ADSs sold to 14.9 million and gross proceeds to about $201.3 million.
Updated with a BusinessWire report · What changed
Updates
· BusinessWire — The offering closed with underwriters fully exercising their option, bringing total ADSs sold to 14.9 million and gross proceeds to about $201.3 million.
Key Events · Financing and Capital Events · SLN
-
Updated · · BusinessWire
Offering Closed with Full Exercise of Option
The offering was expected to close on August 13, 2026, subject to customary closing conditions. It closed with underwriters fully exercising their option, bringing total ADSs sold to 14.9 million and gross proceeds to about $201.3 million.
-
Underwriting Agreement Executed
An underwriting agreement was entered into with Jefferies LLC and Morgan Stanley & Co. LLC as representatives, along with Cantor Fitzgerald & Co and William Blair & Company, L.L.C., to sell 12,962,963 ADSs at a public offering price of $13.50 per ADS.
-
Net Proceeds Estimated at $164M
Net proceeds are estimated at approximately $164.0 million after underwriting discounts and expenses, or $188.7 million if the underwriters' 30-day option to purchase up to 1,944,444 additional ADSs is fully exercised.
-
Offering Priced at $13.50 Per ADS
The public offering price of $13.50 per ADS represents an 8.3% discount to the current stock price of $13.95, with underwriters purchasing at $12.69 per ADS.
Analysis · SLN · Life Sciences
The underwriting agreement for the upsized $175 million public offering has been executed, locking in final terms. Under the deal, 12,962,963 ADSs will be sold at $13.50 per share, with underwriters purchasing at $12.69 per ADS. Net proceeds are estimated at $164 million, or $188.7 million if the 30-day option for 1,944,444 additional ADSs is fully exercised. The offering closed with underwriters fully exercising their option, bringing total ADSs sold to 14.9 million and gross proceeds to about $201.3 million. This capital raise follows the positive Phase 2 SANRECO data for divesiran and significantly extends the company's cash runway. While dilutive to existing shareholders, the offering provides substantial funding for continued development.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 36.4% of the 1059 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SLN was trading at $13.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $695.5M. The 52-week trading range was $4.19 to $17.58. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.